Welcome to our dedicated page for Sionna Therapeutics SEC filings (Ticker: SION), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Sionna Therapeutics, Inc. (Nasdaq: SION) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Sionna describes itself as a clinical-stage biopharmaceutical company focused on developing CFTR-targeted therapies for cystic fibrosis, and its filings offer detail on this business and its financial position.
Among the key documents available are current reports on Form 8-K, where Sionna furnishes press releases announcing quarterly financial results and business highlights. For example, the company has used Form 8-K to present information on research and development expenses, general and administrative expenses, net loss, cash and cash equivalents, and progress across its clinical pipeline of NBD1 stabilizers and complementary CFTR modulators.
In addition to 8-Ks, investors typically look to annual reports on Form 10-K and quarterly reports on Form 10-Q for broader discussions of risk factors, research and development activities, and the company’s focus on cystic fibrosis therapies. These filings can also describe Sionna’s status as an emerging growth company, its operating segment dedicated to CF drug development, and other structural aspects of the business.
Stock Titan enhances access to SION filings by pairing real-time updates from the EDGAR system with AI-powered summaries that explain the significance of each document in clear language. Users can quickly identify items related to clinical trial progress, financial condition, and other material events, and can review insider and management-related disclosures where applicable. This page serves as a central location for reviewing Sionna’s regulatory history and understanding how its CF-focused strategy is reflected in formal SEC documents.
Sionna Therapeutics (SION) filing of a Form 144 notifies the proposed sale of 34,500 shares of common stock through Morgan Stanley Smith Barney LLC on 08/19/2025. The shares have an aggregate market value of $737,955.00 and the company reports 44,139,823 shares outstanding. The securities were acquired on 09/20/2022 through previously exercised stock options from the issuer and were paid for in cash. The filer reports "Nothing to Report" for securities sold during the past three months. The notice includes the filers representation that they do not possess undisclosed material adverse information.
Sionna Therapeutics is a clinical-stage biopharmaceutical company focused on NBD1 stabilizers for cystic fibrosis. For the six months ended June 30, 2025 the company reported a net loss of $34.6 million and an accumulated deficit of $215.6 million. As of June 30, 2025 it held $337.3 million in cash, cash equivalents and marketable securities and raised $199.6 million net proceeds from its IPO. Outstanding common shares were 44.139823 million as of August 1, 2025.
Clinically, Sionna announced positive topline Phase 1 data in over 200 healthy volunteers for lead NBD1 stabilizers SION-719 and SION-451: both were generally well tolerated with no serious adverse events or dose-limiting toxicities and met exposure thresholds the company believes support further development. SION-719 is planned to advance to a Phase 2a add-on trial pending a drug-drug interaction study and SION-451 will advance to a Phase 1 dual-combination trial; both initiations are anticipated in the second half of 2025. Management states existing resources are expected to fund operations into 2028.
Sionna Therapeutics furnished a press release announcing its financial results and business highlights for the quarter ended June 30, 2025. The Form 8-K states the full text of that press release is furnished as Exhibit 99.1 to the Current Report and clarifies that the information is furnished, not filed, so it is not subject to Section 18 liabilities or incorporated by reference in other filings unless expressly stated. The filing also confirms the company’s Delaware incorporation and Nasdaq listing under the ticker SION, and indicates the company qualifies as an emerging growth company. Investors should consult Exhibit 99.1 for the actual financial figures and business highlights.